{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:04:06Z","timestamp":1788919446154,"version":"build-2803163510"},"reference-count":58,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,2,5]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Elevated IL-2R, IL-1RA, and CXCL9 are associated with shorter event-free survival in newly diagnosed FL, treated with chemoimmunotherapy. Increased serum IL-12 and IL-1RA is associated with shorter event-free survival in patients who were observed or treated with rituximab alone.<\/jats:p>","DOI":"10.1182\/blood-2014-06-583369","type":"journal-article","created":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T23:46:18Z","timestamp":1416872778000},"page":"992-998","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":43,"title":["Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma"],"prefix":"10.1182","volume":"125","author":[{"given":"Muhammad A.","family":"Mir","sequence":"first","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-0526","authenticated-orcid":false,"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[{"name":"Biomedical Statistics and Informatics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Ziesmer","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Slager","sequence":"additional","affiliation":[{"name":"Biomedical Statistics and Informatics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Habermann","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Macon","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Link","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Iowa, Iowa City, IA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Syrbu","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Iowa, Iowa City, IA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Witzig","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester, Rochester, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Press","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center\/South West Oncology Group Statistical Center, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center\/South West Oncology Group Statistical Center, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Novak","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111820135031900_B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.beha.2004.06.002","article-title":"The clinical course of follicular lymphoma.","volume":"18","author":"Rohatiner","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"2019111820135031900_B2","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index.","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"22","key":"2019111820135031900_B3","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States.","volume":"23","author":"Swenson","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111820135031900_B4","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2019111820135031900_B5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1080\/10428190601113576","article-title":"Is the follicular lymphoma international prognostic index better than the international prognostic index to identify high-risk follicular lymphoma patients?","volume":"48","author":"Etto","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111820135031900_B6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1385\/MO:23:4:533","article-title":"Predictive value of prognostic indices in patients with follicular lymphomas.","volume":"23","author":"Radojkovic","year":"2006","journal-title":"Med Oncol"},{"issue":"21","key":"2019111820135031900_B7","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111820135031900_B8","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.cyto.2012.08.028","article-title":"Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study.","volume":"60","author":"Charbonneau","year":"2012","journal-title":"Cytokine"},{"issue":"10","key":"2019111820135031900_B9","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood-2011-03-340885","article-title":"Soluble IL-2R\u03b1 facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma.","volume":"118","author":"Yang","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111820135031900_B10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00277-009-0777-8","article-title":"Serum cytokines in follicular lymphoma. Correlation of TGF-\u03b2 and VEGF with survival.","volume":"89","author":"Labidi","year":"2010","journal-title":"Ann Hematol"},{"issue":"12","key":"2019111820135031900_B11","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V96.12.3712","article-title":"Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients.","volume":"96","author":"Salven","year":"2000","journal-title":"Blood"},{"issue":"6","key":"2019111820135031900_B12","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1067\/mai.2003.1594","article-title":"Chemokines: roles in leukocyte development, trafficking, and effector function.","volume":"111","author":"Ono","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2019111820135031900_B13","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMra052723","article-title":"The many roles of chemokines and chemokine receptors in inflammation.","volume":"354","author":"Charo","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111820135031900_B14","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.yexcr.2010.11.013","article-title":"Chemokines in cancer related inflammation.","volume":"317","author":"Allavena","year":"2011","journal-title":"Exp Cell Res"},{"issue":"3","key":"2019111820135031900_B15","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1042\/BJ20071493","article-title":"Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment.","volume":"409","author":"O\u2019Hayre","year":"2008","journal-title":"Biochem J"},{"issue":"4","key":"2019111820135031900_B16","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1189\/jlb.1105633","article-title":"Chemokines, chemokine receptors, and cancer metastasis.","volume":"79","author":"Kakinuma","year":"2006","journal-title":"J Leukoc Biol"},{"issue":"6","key":"2019111820135031900_B17","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1182\/blood-2013-01-481077","article-title":"A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma.","volume":"122","author":"Purdue","year":"2013","journal-title":"Blood"},{"issue":"26","key":"2019111820135031900_B18","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.","volume":"31","author":"Link","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111820135031900_B19","first-page":"95","article-title":"Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma.","volume":"2","author":"Cerhan","year":"2011","journal-title":"Int J Mol Epidemiol Genet"},{"issue":"3","key":"2019111820135031900_B20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","article-title":"Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.","volume":"31","author":"Press","year":"2013","journal-title":"J Clin Oncol"},{"issue":"25","key":"2019111820135031900_B21","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","article-title":"Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin\u2019s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.","volume":"24","author":"Press","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111820135031900_B22","first-page":"843a","article-title":"A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkin\u2019s lymphoma: SWOG 9800 [abstract].","volume":"98","author":"Maloney","year":"2001","journal-title":"Blood"},{"issue":"24","key":"2019111820135031900_B23","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-13-1879","article-title":"Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma.","volume":"19","author":"Marri","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111820135031900_B24","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/ajh.23259","article-title":"Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.","volume":"87","author":"Ansell","year":"2012","journal-title":"Am J Hematol"},{"issue":"24","key":"2019111820135031900_B25","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"issue":"2","key":"2019111820135031900_B26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hon.772","article-title":"Prognosis of follicular lymphomas.","volume":"24","author":"Luminari","year":"2006","journal-title":"Hematol Oncol"},{"issue":"10","key":"2019111820135031900_B27","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdl162","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma.","volume":"17","author":"Gin\u00e9","year":"2006","journal-title":"Ann Oncol"},{"issue":"9","key":"2019111820135031900_B28","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/annonc\/mdi269","article-title":"Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems.","volume":"16","author":"Perea","year":"2005","journal-title":"Ann Oncol"},{"issue":"1","key":"2019111820135031900_B29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-0609.2005.00564.x","article-title":"Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.","volume":"76","author":"Plancarte","year":"2006","journal-title":"Eur J Haematol"},{"key":"2019111820135031900_B30","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3389\/fimmu.2012.00280","article-title":"Stromal cell contribution to human follicular lymphoma pathogenesis.","volume":"3","author":"Mourcin","year":"2012","journal-title":"Front Immunol"},{"issue":"3","key":"2019111820135031900_B31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1158\/1055-9965.EPI-12-0947","article-title":"Non-hodgkin lymphoma and circulating markers of inflammation and adiposity in a nested case-control study: the multiethnic cohort.","volume":"22","author":"Conroy","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"2019111820135031900_B32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(05)70434-4","article-title":"Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium.","volume":"7","author":"Rothman","year":"2006","journal-title":"Lancet Oncol"},{"issue":"19","key":"2019111820135031900_B33","doi-asserted-by":"crossref","first-page":"9771","DOI":"10.1158\/0008-5472.CAN-06-0324","article-title":"Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma.","volume":"66","author":"Wang","year":"2006","journal-title":"Cancer Res"},{"issue":"4","key":"2019111820135031900_B34","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/10428190500361029","article-title":"Aggressive non-Hodgkin\u2019s lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome.","volume":"47","author":"Fabre-Guillevin","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2019111820135031900_B35","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/1097-0142(19940915)74:6<1792::AID-CNCR2820740623>3.0.CO;2-F","article-title":"Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin\u2019s lymphoma. Identification of a subset at high risk of treatment failure.","volume":"74","author":"Stasi","year":"1994","journal-title":"Cancer"},{"issue":"4","key":"2019111820135031900_B36","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/ijc.28724","article-title":"Cytokines in serum in relation to future non-Hodgkin lymphoma risk: evidence for associations by histologic subtype.","volume":"135","author":"Edlefsen","year":"2014","journal-title":"Int J Cancer"},{"issue":"6","key":"2019111820135031900_B37","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1158\/1055-9965.EPI-09-1237","article-title":"Plasma cytokines and future risk of non-Hodgkin lymphoma (NHL): a case-control study nested in the Italian European Prospective Investigation into Cancer and Nutrition.","volume":"19","author":"Saberi Hosnijeh","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"2019111820135031900_B38","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2008-02-138933","article-title":"IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma.","volume":"112","author":"Calvo","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2019111820135031900_B39","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1038\/leu.2010.223","article-title":"Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis.","volume":"24","author":"Pangault","year":"2010","journal-title":"Leukemia"},{"issue":"8","key":"2019111820135031900_B40","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2012-04-421826","article-title":"High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.","volume":"121","author":"Myklebust","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111820135031900_B41","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3109\/10428194.2012.742522","article-title":"Abundant expression of interleukin-21 receptor in follicular lymphoma cells is associated with more aggressive disease.","volume":"54","author":"Wood","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2019111820135031900_B42","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.exphem.2010.02.008","article-title":"Heterogeneous expression and function of IL-21R and susceptibility to IL-21-mediated apoptosis in follicular lymphoma cells.","volume":"38","author":"de Totero","year":"2010","journal-title":"Exp Hematol"},{"issue":"12","key":"2019111820135031900_B43","first-page":"3786","article-title":"IL-1R1\/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice.","volume":"117","author":"Gasse","year":"2007","journal-title":"J Clin Invest"},{"issue":"7332","key":"2019111820135031900_B44","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma.","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"issue":"9","key":"2019111820135031900_B45","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia.","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111820135031900_B46","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.clml.2013.03.014","article-title":"Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma.","volume":"13","author":"Yoshizato","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2019111820135031900_B47","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0923-1811(98)00070-X","article-title":"Serum concentration of the soluble interleukin-2 receptor in vitiligo patients.","volume":"19","author":"Yeo","year":"1999","journal-title":"J Dermatol Sci"},{"issue":"2","key":"2019111820135031900_B48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/jmv.23711","article-title":"Soluble IL-2 receptor and beta-2 microglobulin as possible serologic markers of neurologic disease in HTLV-1 infection.","volume":"86","author":"Toledo-Cornell","year":"2014","journal-title":"J Med Virol"},{"issue":"5","key":"2019111820135031900_B49","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2265.1992.tb02352.x","article-title":"Thyroid function and thyroid autoimmunity independently modulate serum concentration of soluble interleukin 2 (IL-2) receptor (sIL-2R) in thyroid diseases.","volume":"37","author":"Mariotti","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2019111820135031900_B50","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.clinbiochem.2013.11.026","article-title":"Elevated soluble IL-2 receptor levels correlate with tumor bulk of follicular lymphomas with intestinal involvement.","volume":"47","author":"Iwamuro","year":"2014","journal-title":"Clin Biochem"},{"issue":"10","key":"2019111820135031900_B51","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1002\/ijc.25236","article-title":"Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells.","volume":"127","author":"Venetz","year":"2010","journal-title":"Int J Cancer"},{"issue":"3","key":"2019111820135031900_B52","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00277-013-1878-y","article-title":"IP-10\/CXCL10 and MIG\/CXCL9 as novel markers for the diagnosis of lymphoma-associated hemophagocytic syndrome.","volume":"93","author":"Maruoka","year":"2014","journal-title":"Ann Hematol"},{"issue":"2","key":"2019111820135031900_B53","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/1042819031000060546","article-title":"Expression of chemokine receptor CXCR3 and its ligand, mig, in gastric and thyroid marginal zone lymphomas. Possible migration and autocrine mechanism.","volume":"44","author":"Ohshima","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111820135031900_B54","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI59806","article-title":"IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma.","volume":"122","author":"Yang","year":"2012","journal-title":"J Clin Invest"},{"issue":"10","key":"2019111820135031900_B55","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","article-title":"Meta-analysis to evaluate the role of interferon in follicular lymphoma.","volume":"23","author":"Rohatiner","year":"2005","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111820135031900_B56","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1158\/1078-0432.CCR-06-1571","article-title":"A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin\u2019s lymphoma.","volume":"12","author":"Khan","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"20 pt 1","key":"2019111820135031900_B57","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1158\/1078-0432.CCR-06-1245","article-title":"Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin\u2019s lymphoma patients.","volume":"12","author":"Ansell","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2019111820135031900_B58","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1158\/1078-0432.CCR-12-0456","article-title":"A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders.","volume":"18","author":"Timmerman","year":"2012","journal-title":"Clin Cancer Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/6\/992\/1387350\/992.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/6\/992\/1387350\/992.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T20:14:32Z","timestamp":1574108072000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/125\/6\/992\/34087\/Elevated-serum-levels-of-IL2R-IL1RA-and-CXCL9-are"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,5]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,2,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-06-583369","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,5]]}}}